Myriad Completes $80M Acquisition of Rules-Based Medicine

The deal is expected to expand Myriad's product portfolio into new disease areas, including psychiatric disorders, infectious diseases, and inflammatory conditions.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.